Tag - Laau
Mākeke Lapaʻau Depression: ʻO wai ka mea hana nui a He aha ka lāʻau lapaʻau kaulana loa no ka Depression?
Ho'āʻo hou e hoʻomaikaʻi i ka ʻike o ka maʻi Alzheimer
Hoʻopuka ʻo FDA i nā leka aʻo i nā ʻoihana kūʻai hewa ʻole i ka CBD
Haʻawina Pivotal Phase 3 Oral Insulin Study
Metformin maka kulu no ka lapaau ana i ka Macular Degeneration
ʻAe ʻia ʻo FDA no ka mālama hou ʻana o ADHD i nā mākua
Laau Laau Laau Hou no ka Lapaau Ake o Migraine
Hoʻopaneʻe i ka piʻi ʻana i ka dementia o Alzheimer
Ua ʻae ʻo FDA i ka hoʻāʻo ʻana i ka maʻi maʻi maʻi hanu ʻeha
ʻO ka Laʻau Noʻonoʻo Hou no nā maʻi Leukemia Myeloid Acute
Ua ʻae ʻo FDA i ka lapaʻau mua COVID-19 no nā keiki ʻōpio
E hōʻea ʻo Sinus Therapeutic Drugs Market iā US $ 4.29 biliona ma ka hopena o 2030
Hoʻomaka ka ʻikepili ʻikepili ma ke aʻo ʻana i ka maʻi maʻi maʻi metastatic colorectal kiʻekiʻe
ʻO ka hoʻāʻo ʻāina hou no ka Phase 3 Acute Respiratory Distress Syndrome
ʻO ka hoʻāʻo hoʻāʻo hou no ka maʻi maʻi maʻi Lymphoblastic i hoʻihoʻi hou ʻia
Loaʻa i kēia manawa nā hopena o ka hoʻāʻo ʻana i ka maʻi maʻi maʻi maʻi maʻi maʻi COVID-19
ʻO nā pilikia e pili ana me nā hōʻike hoʻāʻo ʻana i ka prenatal non-invasive
Hoʻokō ka hoʻokolohua lapaʻau i ka helu o nā maʻi no ke aʻo ʻana ma ka maʻi Alzheimer
Ua ʻae ʻo FDA i ka hoʻāʻo diagnostic COVID-19 mua me ka hoʻohana ʻana i nā laʻana hanu
Loaʻa ka lāʻau maʻi maʻi maʻi ovarian Platinum-Resistant
ʻO ka hōʻailona hōʻeuʻeu hou no ka maʻi maʻi cervical
Ke ulu nei ka mākeke lāʻau antiviral ma muli o nā lāʻau lapaʻau hou
Mea Hou no ka Therapeutic Effective Against Aggressive Cancer Cells
ʻO ka hoʻāʻo hoʻāʻo hou no nā ʻōpū paʻa kiʻekiʻe a me ka Lymphoma o Hodgkin
ʻO ka hoʻāʻo hoʻāʻo hou o ka hoʻololi ʻana i ke kelepona i ka maʻi o Parkinson
Makeke huahana Microbial Direct-Fed - Ka ulu ʻana, nā helu, ma ka noi, hana, loaʻa a me ka wānana a hiki i 2030
Ua ʻae ʻo FDA i ka implant hou e mālama i ka cartilage a me ka osteochondral defect
Ke hoʻohana nei i nā Cannabinoids e mālama i ka Refractory Epilepsy, Dementia a me Alzheimer
ʻO ka kulu maka hou e mālama i ka ʻike pohihihi pili makahiki
Ua ʻae ʻo FDA i ka Lapaʻau Topical Hou no nā Angiofibromas Maka
Lapaʻau Hou o ka maʻi maʻi prostate kiʻekiʻe
ʻIke Hou e pili ana i ka maʻi o Alzheimer a me Parkinson
Lapaʻau Hou o ka maʻi maʻi prostate kiʻekiʻe i nā mākua
Nā ʻikepili hou no ka mālama ʻana i ka maʻi o Alzheimer
Hoʻokomo hou no nā maʻi ʻeha a me ka osteochondral
ʻO ka lāʻau lapaʻau hou no ka mālama ʻana i ka anemia ma muli o ka maʻi maʻi maʻi maʻi
Noiʻi hou e pili ana i ka hoʻohana ʻana i nā Psychedelics e hakakā i ka maʻi noʻonoʻo
ʻIke hou e pili ana i ka mālama ʻana i nā lapalapa GPP
ʻImi hou no ka mālama ʻana i ka maʻi maʻi pancreatic
Lapaʻau ʻimi noiʻi hou no ka maʻi maʻi lolo
ʻO ke koko hou e wānana i ka maʻi o Alzheimer
ʻO ka hua mua hou o dexmethylphenidate no nā keiki me ADHD
Manaʻo ʻia ʻo Oral Controlled Release Drug Delivery Technology Market e hōʻea i kahi kokoke i US $ 50,000 miliona e 2022-2027.
ʻO ka mua a me ka hoʻopau ʻana i ka maʻi HIV injectable lōʻihi
Laina Laina Mua no ka ma'i ma'i ma'i ma'i 'ole li'ili'i
ʻO nā hoʻokolohua hou no ka maʻi maʻi myeloid acute
Ua ʻae ʻo FDA i ka radioligand therapy no ka maʻi maʻi prostate
ʻO ka Micro-catheter hou e pā i ka mākeke
Ka ʻike pololei ʻana i ka maʻi Alzheimer a me Dementia
ʻO ka maʻi hoʻololi mua no ka maʻi diabetes type 1
Hoʻomaʻemaʻe i ka haʻawina hou no ka mālama ʻana i ka ALS
Laau Laau Laau Hou no ka Lapaau ana i ka Hao
Hoʻopili naʻau hou: Hoʻohana mua ma Florida
Hōʻano hou ʻia nā hopena hoʻāʻo maʻi no ka mālama ʻana i ka maʻi Fabry
ʻO Symbicort generic hou mua i ʻae ʻia e US FDA
ʻO ka hoʻomaha ʻana i ka maʻi maʻi maka hou i nā minuke he 16 mau hola
Hāʻawi ka FDA i ka inoa o nā keiki makua ʻole no ka mālama ʻana iā T-Cell Lymphoma
ʻAe ʻia ka FDA no ka mālama hou ʻana i nā maʻi me ka maʻi Alzheimer
